Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Streaming Portfolio Company Safety Strips, Provides Corporate Update (click to learn more) Saturn Oil & Gas Inc. Announces $525 Million Accretive Core-Area Saskatchewan Asset Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aptevo Therapeutics Inc APVO

Healthcare Biotechnology
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and... see more

Recent & Breaking News (NDAQ:APVO)

Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436

Accesswire October 26, 2021

Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging

Accesswire September 28, 2021

Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Accesswire August 17, 2021

Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights

Accesswire August 12, 2021

Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference

Accesswire July 16, 2021

Aptevo Therapeutics' Scientists to Present At Virtual Cell Engager Summit

Accesswire June 30, 2021

Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index

Accesswire June 29, 2021

Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia

Accesswire May 27, 2021

Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia

Accesswire May 26, 2021

Aptevo Therapeutics Reports First Quarter 2021 Financial Results

Accesswire May 11, 2021

Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting

Accesswire April 9, 2021

Aptevo Therapeutics Reports 2020 Financial Results and Provides Business Update

Accesswire March 31, 2021

Aptevo Confirms Receipt of Nominations and Proposal Notice

Accesswire February 9, 2021

Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial

Accesswire January 11, 2021

Kaskela Law LLC Announces Investigation of Aptevo Therapeutics Inc. (APVO) and Encourages Shareholders to Contact the Firm

ACCESSWIRE IA December 19, 2020

Aptevo Therapeutics Announces the Launch of Its Second Platform Technology ADAPTIR-FLEX(TM) and Introduces the New Bispecific Prostate Cancer Candidate APVO442

Accesswire December 2, 2020

Aptevo Confirms Receipt of Unsolicited Indication of Interest

Accesswire November 19, 2020

Aptevo Therapeutics and Alligator Bioscience Advancing the Bispecific 4-1BBx5T4 Antibody ALG.APV-527 Into Phase 1 Clinical Development

Accesswire November 16, 2020

Aptevo Therapeutics Reports Third Quarter Financial Results and Provides Business Update

Accesswire November 10, 2020

Aptevo Therapeutics to Present at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting

Accesswire November 9, 2020